Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate

Leukemia

Volumn 17, Issue 3, 2003, Pages 481-487

  O'Dwyer, M E ^a   Gatter, K M ^a   Loriaux, M ^a   Druker, B J ^a   Olson, S B ^b   Magenis, R E ^b   Lawce, H ^b   Mauro, M J ^a   Maziarz, R T ^a   Braziel, R M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Clonal abnormalities; CML; Imatinib mesylate; MDS; ST1571

Indexed keywords

BCR ABL PROTEIN; IMATINIB; INTERFERON;

ADULT; ANEMIA; ARTICLE; BLAST CELL; BONE MARROW CELL; CELL CLONING; CELL COUNT; CELL STRUCTURE; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DRUG RESPONSE; DYSPLASIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE REARRANGEMENT; GENETIC DISORDER; GENETIC SCREENING; HUMAN; HUMAN CELL; MALE; MEDICAL DOCUMENTATION; METAPHASE CHROMOSOME; NEUTROPENIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; THROMBOCYTOPENIA; TRISOMY 8;

EID: 0345382731     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402848     Document Type: Article

References (20)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497-1501.
2. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
3. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985; 315: 550-554.
4. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
5. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products. Science 1990; 247: 1079-1082.
6. Druker BJ, Talpaz M, Resta DJ, Phen B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BDR-ABL tyrosine kinase in chronic myelogenous leukemia. N Engl J Med 2001; 344: 1031-1037.
7. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
8. Druker BJ. STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN)+cytarabine as initial therapy for patients with CML: results of a randomized study. Proc. ASCO 2002; 21: 1a (Abstract).
9. Marktel S, Bua M, Marin D, Chase A, Udom C, Armstrong L et al. Emergence of additional chromosomal abnormalities following treatment with STI571 (imatinib mesylate) for Philadelphia positive chronic myelogenous leukemia in chronic phase. Proc Am Soc Hematol 2001 (Abstract 2584).
10. Mohamed AN, Pemberton P, Zonder JA, Homisha S, Ford J, Schiffer CA. The effect of Gleevec (STI571;imatinib mesylate) in patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) with secondary chromosomal aberrations. Proc Am Soc Hematol 2001 (Abstract 2343).
11. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937.
12. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999; 340: 1649-1660.
13. Fayad L, Kantarjian H, O'Brien S, Seong D, Albitar M, Keating M, et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 1997; 11: 767-771.
14. Bilhou-Nabera C, Marit G, Devianne I, Viard F, Salzes S, Montastruc M, et al. A second case of trisomy 8 in Philadelphia chromosome (Ph)-negative cells during the course of Ph-positive chronic myelocytic leukemia. Genes Chromosomes Cancer 1993; 6: 255-256.
15. Ariyama T, Inazawa J, Uemura Y, Kakazu N, Maekawa T, Urase F et al. Clonal origin of Philadelphia chromosome negative cells with trisomy 8 appearing during the course of alpha-interferon therapy for Ph positive chronic myelocytic leukemia. Cancer Genet Cytogenet 1995; 81: 20-23.
16. Maserati E, Aprili F, Vinante F, Locatelli F, Amendola G, Zatterale A et al. Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15-20% of cases. Genes Chromosomes Cancer 2002; 33: 93-97.
17. Granada I, Luno E, Ribera JM, Sanzo C, Muniz SG, Milla F. Translocation (3;10)(q26;q22): a new nonrandom abnormality in three patients with 3q26 involvement. Cancer Genet Cytogenet 2000; 121: 99-100.
18. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925-932.
19. Lyman SD, Jacobsen SE. c-Kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91: 1101-1134.
20. Anderson MK, Pdersen-Bjergaard, Kjeldsen L, Dufva IH, Brondum-Nielsen K. Clonal Ph-negative hematopoiesis in CML after therapy. Leukemia 2002; 16: 1390-1393.